Communication
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation*
*
This work was supported by the US National Institutes of Health: 5DP1OD006933 (NIH Director’s Pioneer Award) to S.W.F., an ARRA stimulus grant (5RC2A148375) to L. J. Marnett, and a NCI SPORE grant in GI cancer (5P50A095103‐09) to R.J. Coffey. This work was also funded by the Lustgarten Foundation grant awarded to S.W.F. and the American Cancer Society (Postdoctoral Fellowship, PF1110501CDD) to J.P.B. We thank Matt Mulder (Craig Lindsley lab, Vanderbilt University) for providing HRMS data.
Abstract
Looking for fragments: A fragment‐based screen using NMR spectroscopy was applied to discover ligands that bind to the GTPase K‐Ras and modulate the activity of the nucleotide exchange factor Sos. Structural data on how these fragment‐derived hits bind to the guanosine diphosphate–K‐Ras complex (see picture) provides a starting point for the future discovery of drugs that target K‐Ras activation and signaling.
Citing Literature
Number of times cited: 177
- Vincent Bernard and Anirban Maitra, Targeted Therapies for Pancreatic Cancer, The Pancreas, (865-871), (2018).
- Nagore I. Marín-Ramos, Silvia Ortega-Gutiérrez and María L. López-Rodríguez, Blocking Ras inhibition as an antitumor strategy, Seminars in Cancer Biology, (2018).
- Hiu Yeung Lau and Mei Wang, Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation, Small GTPases, (1), (2018).
- Michael C. Burns, Jennifer E. Howes, Qi Sun, Andrew J. Little, DeMarco V. Camper, Jason R. Abbott, Jason Phan, Taekyu Lee, Alex G. Waterson, Olivia W. Rossanese and Stephen W. Fesik, High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling, Analytical Biochemistry, (2018).
- Matthew R. Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J. Firdaus, Levan Darjania, Jun Feng, Jeffrey H. Chen, Shuangwei Li, Shisheng Li, Yun O. Long, Carol Thach, Yuan Liu, Ata Zarieh, Tess Ely, Jeff M. Kucharski, Linda V. Kessler, Tao Wu, Ke Yu, Yi Wang, Yvonne Yao, Xiaohu Deng, Patrick P. Zarrinkar, Dirk Brehmer, Dashyant Dhanak, Matthew V. Lorenzi, Dana Hu-Lowe, Matthew P. Patricelli, Pingda Ren and Yi Liu, Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor, Cell, 172, 3, (578), (2018).
- Roberto Serna-Blasco, Marta Sanz-Álvarez, Óscar Aguilera and Jesús García-Foncillas, Targeting the RAS-dependent chemoresistance: the Warburg connection, Seminars in Cancer Biology, (2018).
- , NMR-Fragment Based Virtual Screening: A Brief Overview, Molecules, 23, 2, (233), (2018).
- Naveen A. Mallangada, Joselin M. Vargas, Swaroopa Thomas, Matthew G. DiGiovanni, Brandon M. Vaeth, Matthew D. Nemesure, Ruixue Wang, Joseph F. LaComb, Jennie L. Williams, Lorne M. Golub, Francis Johnson and Gerardo G. Mackenzie, A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras, Molecular Carcinogenesis, 57, 9, (1130-1143), (2018).
- Pablo Martín‐Gago, Eyad K. Fansa, Christian H. Klein, Sandip Murarka, Petra Janning, Marc Schürmann, Malte Metz , Shehab Ismail, Carsten Schultz‐Fademrecht, Matthias Baumann, Philippe I. H. Bastiaens, Alfred Wittinghofer and Herbert Waldmann, A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2, Angewandte Chemie, 129, 9, (2463-2468), (2017).
- Sandip Murarka, Pablo Martín‐Gago, Carsten Schultz‐Fademrecht, Alaa Al Saabi, Matthias Baumann, Eyad K. Fansa, Shehab Ismail, Peter Nussbaumer, Alfred Wittinghofer and Herbert Waldmann, Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site, Chemistry – A European Journal, 23, 25, (6083-6093), (2016).
- Pablo Martín‐Gago, Eyad K. Fansa, Christian H. Klein, Sandip Murarka, Petra Janning, Marc Schürmann, Malte Metz , Shehab Ismail, Carsten Schultz‐Fademrecht, Matthias Baumann, Philippe I. H. Bastiaens, Alfred Wittinghofer and Herbert Waldmann, A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2, Angewandte Chemie International Edition, 56, 9, (2423-2428), (2017).
- Sameeksha Tiwari, Manika Awasthi, Swati Singh, Veda P. Pandey and Upendra N. Dwivedi, Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment, Journal of Biomolecular Structure and Dynamics, (1), (2017).
- Christopher H. Gray, Jennifer Konczal, Mokdad Mezna, Shehab Ismail, Justin Bower and Martin Drysdale, A fully automated procedure for the parallel, multidimensional purification and nucleotide loading of the human GTPases KRas, Rac1 and RalB, Protein Expression and Purification, 132, (75), (2017).
- Russell Spencer-Smith, Lie Li, Sheela Prasad, Akiko Koide, Shohei Koide and John P. O'Bryan, Targeting the α4-α5 interface of RAS results in multiple levels of inhibition, Small GTPases, (1), (2017).
- A.L. Breeze, Fragment-Based Drug Design by NMR, Encyclopedia of Spectroscopy and Spectrometry, 10.1016/B978-0-12-409547-2.12119-5, (741-749), (2017).
- Matthew E. Welsch, Anna Kaplan, Jennifer M. Chambers, Michael E. Stokes, Pieter H. Bos, Arie Zask, Yan Zhang, Marta Sanchez-Martin, Michael A. Badgley, Christine S. Huang, Timothy H. Tran, Hemanth Akkiraju, Lewis M. Brown, Renu Nandakumar, Serge Cremers, Wan Seok Yang, Liang Tong, Kenneth P. Olive, Adolfo Ferrando and Brent R. Stockwell, Multivalent Small-Molecule Pan-RAS Inhibitors, Cell, 168, 5, (878), (2017).
- Satoshi Sogabe, Yusuke Kamada, Masanori Miwa, Ayumu Niida, Tomoya Sameshima, Masahiro Kamaura, Kazuko Yonemori, Shigekazu Sasaki, Jun-ichi Sakamoto and Kotaro Sakamoto, Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d, ACS Medicinal Chemistry Letters, 8, 7, (732), (2017).
- Yan Jiang, Chunlin Zhuang, Long Chen, Junjie Lu, Guoqiang Dong, Zhenyuan Miao, Wannian Zhang, Jian Li and Chunquan Sheng, Structural Biology-Inspired Discovery of Novel KRAS–PDEδ Inhibitors, Journal of Medicinal Chemistry, 10.1021/acs.jmedchem.7b01243, 60, 22, (9400-9406), (2017).
- Monique J. Kauke, Michael W. Traxlmayr, Jillian A. Parker, Jonathan D. Kiefer, Ryan Knihtila, John McGee, Greg Verdine, Carla Mattos and K. Dane Wittrup, An engineered protein antagonist of K-Ras/B-Raf interaction, Scientific Reports, 7, 1, (2017).
- Ayumu Niida, Shigekazu Sasaki, Kazuko Yonemori, Tomoya Sameshima, Masahiro Yaguchi, Taiji Asami, Kotaro Sakamoto and Masahiro Kamaura, Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging, Bioorganic & Medicinal Chemistry Letters, 27, 12, (2757), (2017).
- I.R. Hardcastle, Protein–Protein Interaction Inhibitors in Cancer, Comprehensive Medicinal Chemistry III, 10.1016/B978-0-12-409547-2.12392-3, (154-201), (2017).
- Adam M. Levinson, John H. McGee, Andrew G. Roberts, Gardner S. Creech, Ting Wang, Michael T. Peterson, Ronald C. Hendrickson, Gregory L. Verdine and Samuel J. Danishefsky, Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V) , Journal of the American Chemical Society, 10.1021/jacs.7b02988, 139, 22, (7632-7639), (2017).
- Johanna M. Jansen, Charles Wartchow, Wolfgang Jahnke, Susan Fong, Tiffany Tsang, Keith Pfister, Tatiana Zavorotinskaya, Dirksen Bussiere, Jan Marie Cheng, Kenneth Crawford, Yumin Dai, Jeffrey Dove, Eric Fang, Yun Feng, Jean-Michel Florent, John Fuller, Alvar D. Gossert, Mohammad Hekmat-Nejad, Chrystèle Henry, Julia Klopp, William P. Lenahan, Andreas Lingel, Sylvia Ma, Arndt Meyer, Yuji Mishina, Jamie Narberes, Gwynn Pardee, Savithri Ramurthy, Sebastien Rieffel, Darrin Stuart, Sharadha Subramanian, Laura Tandeske, Stephania Widger, Armin Widmer, Aurelie Winterhalter, Isabel Zaror, Stephen Hardy and Michael F Olson, Inhibition of prenylated KRAS in a lipid environment, PLOS ONE, 12, 4, (e0174706), (2017).
- H. Billur Engin, Daniel Carlin, Dexter Pratt and Hannah Carter, Modeling of RAS complexes supports roles in cancer for less studied partners, BMC Biophysics, 10.1186/s13628-017-0037-6, 10, S1, (2017).
- Syed Lal Badshah and Yahia Mabkhot, Arresting kinase suppressor of Ras in an inactive state, Chinese Journal of Cancer, 10.1186/s40880-017-0181-z, 36, 1, (2017).
- Mei Zeng, Jia Lu, Lianbo Li, Frederic Feru, Chunshan Quan, Thomas W. Gero, Scott B. Ficarro, Yuan Xiong, Chiara Ambrogio, Raymond M. Paranal, Marco Catalano, Jay Shao, Kwok-Kin Wong, Jarrod A. Marto, Eric S. Fischer, Pasi A. Jänne, David A. Scott, Kenneth D. Westover and Nathanael S. Gray, Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C, Cell Chemical Biology, 24, 8, (1005), (2017).
- Dhirendra K. Simanshu, Dwight V. Nissley and Frank McCormick, RAS Proteins and Their Regulators in Human Disease, Cell, 10.1016/j.cell.2017.06.009, 170, 1, (17-33), (2017).
- Bjoern Papke and Channing J. Der, Drugging RAS: Know the enemy, Science, 355, 6330, (1158), (2017).
- Nagore I. Marín‐Ramos, Carmen Piñar, Henar Vázquez‐Villa, Mar Martín‐Fontecha, Ángel González, Ángeles Canales, Sergio Algar, Paloma P. Mayo, Jesús Jiménez‐Barbero, Consuelo Gajate, Faustino Mollinedo, Leonardo Pardo, Silvia Ortega‐Gutiérrez, Alma Viso and María L. López‐Rodríguez, Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling, Chemistry – A European Journal, 23, 7, (1676-1685), (2016).
- Russell Spencer-Smith and John P. O’Bryan, Direct inhibition of RAS: Quest for the Holy Grail?, Seminars in Cancer Biology, 10.1016/j.semcancer.2017.12.005, (2017).
- Minsig Choi, Harold Bien, Adaobi Mofunanya and Scott Powers, Challenges in Ras therapeutics in pancreatic cancer, Seminars in Cancer Biology, (2017).
- Mandar Deepak Muzumdar, Pan-Yu Chen, Kimberly Judith Dorans, Katherine Minjee Chung, Arjun Bhutkar, Erin Hong, Elisa M. Noll, Martin R. Sprick, Andreas Trumpp and Tyler Jacks, Survival of pancreatic cancer cells lacking KRAS function, Nature Communications, 8, 1, (2017).
- Lynn M. McGregor, Meredith L. Jenkins, Caitlin Kerwin, John E. Burke and Kevan M. Shokat, Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes, Biochemistry, 56, 25, (3178), (2017).
- Nicolas Jonckheere, Romain Vasseur and Isabelle Van Seuningen, The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting, Critical Reviews in Oncology/Hematology, 10.1016/j.critrevonc.2017.01.002, 111, (7-19), (2017).
- Ruth Nussinov, Hyunbum Jang, Chung-Jung Tsai, Tsung-Jen Liao, Shuai Li, David Fushman and Jian Zhang, Intrinsic protein disorder in oncogenic KRAS signaling, Cellular and Molecular Life Sciences, 10.1007/s00018-017-2564-3, 74, 17, (3245-3261), (2017).
- A.B. Keeton and G.A. Piazza, Search for Inhibitors of Ras-Driven Cancers, Conquering RAS, 10.1016/B978-0-12-803505-4.00008-4, (135-154), (2017).
- Brooke Bullock Lao and Paramjit S. Arora, Oligooxopiperazines as Topographical Helix Mimetics, Peptidomimetics II, 10.1007/7081_2015_195, (1-24), (2016).
- Thomas Kodadek, Another One (of the “Undruggable” Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP, Biochemistry, (2017).
- Russell Spencer-Smith, Akiko Koide, Yong Zhou, Raphael R Eguchi, Fern Sha, Priyanka Gajwani, Dianicha Santana, Ankit Gupta, Miranda Jacobs, Erika Herrero-Garcia, Jacqueline Cobbert, Hugo Lavoie, Matthew Smith, Thanashan Rajakulendran, Evan Dowdell, Mustafa Nazir Okur, Irina Dementieva, Frank Sicheri, Marc Therrien, John F Hancock, Mitsuhiko Ikura, Shohei Koide and John P O'Bryan, Inhibition of RAS function through targeting an allosteric regulatory site, Nature Chemical Biology, 13, 1, (62), (2017).
- Miriam Schöpel, Christian Herrmann, Jürgen Scherkenbeck, Raphael Stoll and Christian Griesinger, The Bisphenol A analogue Bisphenol S binds to K‐Ras4B – implications for ‘BPA‐free’ plastics, FEBS Letters, 590, 3, (369-375), (2016).
- Yunyun Mao, Haijie Yao, Hui Wang, Peng Cheng and Dong Long, Microsecond Timescale Dynamics of GDP‐Bound Ras Underlies the Formation of Novel Inhibitor‐Binding Pockets, Angewandte Chemie International Edition, 55, 50, (15629-15632), (2016).
- Yunyun Mao, Haijie Yao, Hui Wang, Peng Cheng and Dong Long, Microsecond Timescale Dynamics of GDP‐Bound Ras Underlies the Formation of Novel Inhibitor‐Binding Pockets, Angewandte Chemie, 128, 50, (15858-15861), (2016).
- Biagio Ricciuti, Giulia Costanza Leonardi, Giulio Metro, Francesco Grignani, Luca Paglialunga, Guido Bellezza, Sara Baglivo, Clelia Mencaroni, Alice Baldi, Daniela Zicari and Lucio Crinò, Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications, Expert Review of Respiratory Medicine, 10, 1, (53), (2016).
- Yasmine White, Aditi Bagchi, Jessica Van Ziffle, Anagha Inguva, Gideon Bollag, Chao Zhang, Heidi Carias, David Dickens, Mignon Loh, Kevin Shannon and Ari J. Firestone, KRAS insertion mutations are oncogenic and exhibit distinct functional properties, Nature Communications, 7, (10647), (2016).
- Candice Y. Wilson and Peter Tolias, Recent advances in cancer drug discovery targeting RAS, Drug Discovery Today, 21, 12, (1915), (2016).
- Shaoyong Lu, Hyunbum Jang, Serena Muratcioglu, Attila Gursoy, Ozlem Keskin, Ruth Nussinov and Jian Zhang, Ras Conformational Ensembles, Allostery, and Signaling, Chemical Reviews, 10.1021/acs.chemrev.5b00542, 116, 11, (6607-6665), (2016).
- Cormac Sheridan, Drug developers refocus efforts on RAS, Nature Biotechnology, 34, 3, (217), (2016).
- Pascale Tomasini, Preet Walia, Catherine Labbe, Kevin Jao and Natasha B. Leighl, Targeting the KRAS Pathway in Non‐Small Cell Lung Cancer, The Oncologist, 21, 12, (1450-1460), (2016).
- Roderick E. Hubbard, The Role of Fragment‐based Discovery in Lead Finding, Fragment‐based Drug Discovery Lessons and Outlook, (1-36), (2016).
- Feng Wang and Stephen W. Fesik, Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods, Fragment‐based Drug Discovery Lessons and Outlook, (371-390), (2016).
- György M. Keserű, Daniel A. Erlanson, György G. Ferenczy, Michael M. Hann, Christopher W. Murray and Stephen D. Pickett, Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia, Journal of Medicinal Chemistry, 59, 18, (8189), (2016).
- G. Aaron Hobbs, Alfred Wittinghofer and Channing J. Der, Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down, Cancer Cell, 29, 3, (251), (2016).
- Shaoyong Lu, Hyunbum Jang, Shuo Gu, Jian Zhang and Ruth Nussinov, Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view, Chem. Soc. Rev., 10.1039/C5CS00911A, 45, 18, (4929-4952), (2016).
- Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard, Wolfgang Jahnke and Harren Jhoti, Twenty years on: the impact of fragments on drug discovery, Nature Reviews Drug Discovery, 15, 9, (605), (2016).
- Shigeyuki Matsumoto, Nao Miyano, Seiki Baba, Jingling Liao, Takashi Kawamura, Chiemi Tsuda, Azusa Takeda, Masaki Yamamoto, Takashi Kumasaka, Tohru Kataoka and Fumi Shima, Molecular Mechanism for Conformational Dynamics of Ras·GTP Elucidated from In-Situ Structural Transition in Crystal, Scientific Reports, 6, 1, (2016).
- Christian Posch, Igor Vujic, Babak Monshi, Martina Sanlorenzo, Felix Weihsengruber, Klemens Rappersberger and Susana Ortiz-Urda, Searching for the Chokehold of NRAS Mutant Melanoma, Journal of Investigative Dermatology, 10.1016/j.jid.2016.03.006, 136, 7, (1330-1336), (2016).
- Shaoyong Lu, Hyunbum Jang, Ruth Nussinov and Jian Zhang, The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B, Scientific Reports, 10.1038/srep21949, 6, 1, (2016).
- Shaoyong Lu, Hyunbum Jang, Jian Zhang and Ruth Nussinov, Inhibitors of Ras–SOS Interactions, ChemMedChem, 11, 8, (814-821), (2015).
- Milind Javle, Talia Golan and Anirban Maitra, Changing the course of pancreatic cancer – Focus on recent translational advances, Cancer Treatment Reviews, 44, (17), (2016).
- Shun Ying Quah, Michelle Siying Tan, Yuan Han Teh and Johnson Stanslas, Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2016.03.010, 162, (35-57), (2016).
- Thi B. Trinh, Punit Upadhyaya, Ziqing Qian and Dehua Pei, Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides, ACS Combinatorial Science, 10.1021/acscombsci.5b00164, 18, 1, (75-85), (2016).
- Nora Rauch, Oleksii S Rukhlenko, Walter Kolch and Boris N Kholodenko, MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance, Current Opinion in Structural Biology, 41, (151), (2016).
- Jean-Paul Renaud, Chun-wa Chung, U. Helena Danielson, Ursula Egner, Michael Hennig, Roderick E. Hubbard and Herbert Nar, Biophysics in drug discovery: impact, challenges and opportunities, Nature Reviews Drug Discovery, 15, 10, (679), (2016).
- Gajendra Shrestha, Shelley M. MacNeil, Jasmine A. McQuerry, David F. Jenkins, Sunil Sharma and Andrea H. Bild, The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers, Seminars in Cell & Developmental Biology, 58, (108), (2016).
- Daniel Zeitouni, Yuliya Pylayeva-Gupta, Channing Der and Kirsten Bryant, KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment, Cancers, 8, 12, (45), (2016).
- Ashley E. Modell, Sarah L. Blosser and Paramjit S. Arora, Systematic Targeting of Protein–Protein Interactions, Trends in Pharmacological Sciences, 10.1016/j.tips.2016.05.008, 37, 8, (702-713), (2016).
- Sunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Anastasia K. Yocum, Harika Gundlapalli, Yasmine White, Ari Firestone, Xuhong Cao, Saravana M. Dhanasekaran, Jeanne A. Stuckey, Gideon Bollag, Kevin Shannon, Nils G. Walter, Chandan Kumar-Sinha and Arul M. Chinnaiyan, KRAS Engages AGO2 to Enhance Cellular Transformation, Cell Reports, 14, 6, (1448), (2016).
- Priyanka Prakash, John F. Hancock and Alemayehu A. Gorfe, Binding hotspots on K‐ras: Consensus ligand binding sites and other reactive regions from probe‐based molecular dynamics analysis, "Proteins: Structure, Function, and Bioinformatics", 83, 5, (898-909), (2015).
- Tomasz Cierpicki and Jolanta Grembecka, Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?, Immunological Reviews, 263, 1, (279-301), (2014).
- Philipp M. Cromm, Jochen Spiegel, Tom N. Grossmann and Herbert Waldmann, Direkte Modulation von Aktivität und Funktion kleiner GTPasen, Angewandte Chemie, 127, 46, (13718-13741), (2015).
- Punit Upadhyaya, Ziqing Qian, Nicholas G. Selner, Sarah R. Clippinger, Zhengrong Wu, Roger Briesewitz and Dehua Pei, Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides, Angewandte Chemie International Edition, 54, 26, (7602-7606), (2015).
- Punit Upadhyaya, Ziqing Qian, Nicholas G. Selner, Sarah R. Clippinger, Zhengrong Wu, Roger Briesewitz and Dehua Pei, Inhibition of Ras Signaling by Blocking Ras–Effector Interactions with Cyclic Peptides, Angewandte Chemie, 127, 26, (7712-7716), (2015).
- Philipp M. Cromm, Jochen Spiegel, Tom N. Grossmann and Herbert Waldmann, Direct Modulation of Small GTPase Activity and Function, Angewandte Chemie International Edition, 54, 46, (13516-13537), (2015).
- Duncan E. Scott, Anthony G. Coyne, Ashok Venkitaraman, Tom L. Blundell, Chris Abell and Marko Hyvönen, Small‐Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases, ChemMedChem, 10, 2, (296-303), (2014).
- Tanmay S. Chavan, Hyunbum Jang, Lyuba Khavrutskii, Sherwin J. Abraham, Avik Banerjee, Benjamin C. Freed, Liv Johannessen, Sergey G. Tarasov, Vadim Gaponenko, Ruth Nussinov and Nadya I. Tarasova, High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site, Biophysical Journal, 109, 12, (2602), (2015).
- Chris R. Evelyn, Jacek Biesiada, Xin Duan, Hong Tang, Xun Shang, Ruben Papoian, William L. Seibel, Sandra Nelson, Jaroslaw Meller and Yi Zheng, Combined Rational Design and a High Throughput Screening Platform for Identifying Chemical Inhibitors of a Ras-activating Enzyme, Journal of Biological Chemistry, 290, 20, (12879), (2015).
- Markus O. Zimmermann, Andreas Lange and Frank M. Boeckler, Evaluating the Potential of Halogen Bonding in Molecular Design: Automated Scaffold Decoration Using the New Scoring Function XBScore, Journal of Chemical Information and Modeling, 10.1021/ci5007118, 55, 3, (687-699), (2015).
- Carmen Avendaño and J. Carlos Menéndez, Other Nonbiological Approaches to Targeted Cancer Chemotherapy, Medicinal Chemistry of Anticancer Drugs, 10.1016/B978-0-444-62649-3.00011-9, (493-560), (2015).
- Priyanka Prakash, Abdallah Sayyed-Ahmad, Alemayehu A. Gorfe and Amarda Shehu, pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins, PLOS Computational Biology, 11, 10, (e1004469), (2015).
- Kyle Knickelbein and Lin Zhang, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes & Diseases, 2, 1, (4), (2015).
- R. Shirakawa and H. Horiuchi, Ral GTPases: crucial mediators of exocytosis and tumourigenesis, Journal of Biochemistry, 157, 5, (285), (2015).
- Abhijeet Kapoor and Alex Travesset, Differential dynamics of RAS isoforms in GDP‐ and GTP‐bound states, "Proteins: Structure, Function, and Bioinformatics", 83, 6, (1091-1106), (2015).
- Chao Yan and Dan Theodorescu, One step closer to targeting RAS, Cell Cycle, 14, 3, (287), (2015).
- Elizaveta S. Leshchiner, Andrey Parkhitko, Gregory H. Bird, James Luccarelli, Joseph A. Bellairs, Silvia Escudero, Kwadwo Opoku-Nsiah, Marina Godes, Norbert Perrimon and Loren D. Walensky, Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices, Proceedings of the National Academy of Sciences, 112, 6, (1761), (2015).
- Jon J. G. Winter, Malcolm Anderson, Kevin Blades, Claire Brassington, Alexander L. Breeze, Christine Chresta, Kevin Embrey, Gary Fairley, Paul Faulder, M. Raymond V. Finlay, Jason G. Kettle, Thorsten Nowak, Ross Overman, S. Joe Patel, Paula Perkins, Loredana Spadola, Jonathan Tart, Julie A. Tucker and Gail Wrigley, Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation, Journal of Medicinal Chemistry, 58, 5, (2265), (2015).
- Shaoyong Lu, Avik Banerjee, Hyunbum Jang, Jian Zhang, Vadim Gaponenko and Ruth Nussinov, GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site, Journal of Biological Chemistry, 290, 48, (28887), (2015).
- Malgorzata Skwarczynska and Christian Ottmann, Protein–protein interactions as drug targets, Future Medicinal Chemistry, 10.4155/fmc.15.138, 7, 16, (2195-2219), (2015).
- Clare Sheridan and Julian Downward, Overview of KRAS‐Driven Genetically Engineered Mouse Models of Non‐Small Cell Lung Cancer, Current Protocols in Pharmacology, 70, 1, (14.35.1-14.35.16), (2015).
- Andrew M. Watkins and Paramjit S. Arora, Structure-based inhibition of protein–protein interactions, European Journal of Medicinal Chemistry, 10.1016/j.ejmech.2014.09.047, 94, (480-488), (2015).
- Fumi Shima, Shigeyuki Matsumoto, Yoko Yoshikawa, Takashi Kawamura, Masayuki Isa and Tohru Kataoka, Current status of the development of Ras inhibitors, Journal of Biochemistry, 10.1093/jb/mvv060, 158, 2, (91-99), (2015).
- Gerhard Fischer, Maxim Rossmann and Marko Hyvönen, Alternative modulation of protein–protein interactions by small molecules, Current Opinion in Biotechnology, 10.1016/j.copbio.2015.04.006, 35, (78-85), (2015).
- Meagan B. Ryan, Channing J. Der, Andrea Wang-Gillam and Adrienne D. Cox, Targeting RAS-mutant Cancers: Is ERK the Key?, Trends in Cancer, 1, 3, (183), (2015).
- Thomas V. Magee, Progress in discovery of small-molecule modulators of protein–protein interactions via fragment screening, Bioorganic & Medicinal Chemistry Letters, 25, 12, (2461), (2015).
- Chao Yan, David NM Jones and Dan Theodorescu, Drugging the Ral GTPase, Small GTPases, 10.1080/21541248.2015.1018403, 6, 3, (157-159), (2015).
- Dima Kozakov, David R. Hall, Raeanne L. Napoleon, Christine Yueh, Adrian Whitty and Sandor Vajda, New Frontiers in Druggability, Journal of Medicinal Chemistry, 10.1021/acs.jmedchem.5b00586, 58, 23, (9063-9088), (2015).
- Joseph Carver, Thomas S. Dexheimer, Dennis Hsu, Meng-Tzu Weng, Jordan L. Smith, Rajarshi Guha, Ajit Jadhav, Anton Simeonov, Ji Luo and Richard Y. Zhao, A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein, PLoS ONE, 9, 8, (e103836), (2014).
- Chao Yan, Degang Liu, Liwei Li, Michael F. Wempe, Sunny Guin, May Khanna, Jeremy Meier, Brenton Hoffman, Charles Owens, Christina L. Wysoczynski, Matthew D. Nitz, William E. Knabe, Mansoor Ahmed, David L. Brautigan, Bryce M. Paschal, Martin A. Schwartz, David N. M. Jones, David Ross, Samy O. Meroueh and Dan Theodorescu, Discovery and characterization of small molecules that target the GTPase Ral, Nature, 515, 7527, (443), (2014).
- Martin Augsten, Anika Böttcher, Rainer Spanbroek, Ignacio Rubio and Karlheinz Friedrich, Graded Inhibition of Oncogenic Ras-Signaling by Multivalent Ras-Binding Domains, Cancer Cell Signaling, 10.1201/b17138-3, (27-53), (2014).
- Priyanka Prakash and Alemayehu A. Gorfe, Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras, Molecular Simulation, 10.1080/08927022.2014.895000, 40, 10-11, (839-847), (2014).
- Ahmed A. Samatar and Poulikos I. Poulikakos, Targeting RAS–ERK signalling in cancer: promises and challenges, Nature Reviews Drug Discovery, 13, 12, (928), (2014).
- Tzu-Chieh Hung, Wen-Yuan Lee, Kuen-Bao Chen, Yueh-Chiu Chan and Calvin Yu-Chian Chen, An Investigation of Small GTPases in relation to Liver Tumorigenesis Using Traditional Chinese Medicine, BioMed Research International, 10.1155/2014/428210, 2014, (1-11), (2014).
- Charles Wartchow, Theoretical Considerations of the Application of DNA‐Encoded Libraries to Drug Discovery, A Handbook for DNA‐Encoded Chemistry, (213-230), (2014).
- Jochen Spiegel, Philipp M. Cromm, Aymelt Itzen, Roger S. Goody, Tom N. Grossmann and Herbert Waldmann, Direkte Modulation von Rab‐GTPase‐Effektor‐Wechselwirkungen, Angewandte Chemie, 126, 9, (2531-2536), (2014).
- S Eser, A Schnieke, G Schneider and D Saur, Oncogenic KRAS signalling in pancreatic cancer, British Journal of Cancer, 10.1038/bjc.2014.215, 111, 5, (817-822), (2014).
- Punit Upadhyaya, Ziqing Qian, Nurlaila A.A. Habir and Dehua Pei, Direct Ras inhibitors identified from a structurally rigidified bicyclic peptide library, Tetrahedron, 10.1016/j.tet.2014.05.113, 70, 42, (7714-7720), (2014).
- I. I. C. Chio, G. Yordanov and D. Tuveson, MAX-ing Out MYC: A Novel Small Molecule Inhibitor Against MYC-Dependent Tumors, JNCI Journal of the National Cancer Institute, 106, 12, (dju365), (2014).
- Kirsten L. Bryant, Joseph D. Mancias, Alec C. Kimmelman and Channing J. Der, KRAS: feeding pancreatic cancer proliferation, Trends in Biochemical Sciences, 39, 2, (91), (2014).
- Paul A. Hubbard, Colleen L. Moody and Ramachandran Murali, Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities, Frontiers in Physiology, 5, (2014).
- J. C. Hunter, D. Gurbani, S. B. Ficarro, M. A. Carrasco, S. M. Lim, H. G. Choi, T. Xie, J. A. Marto, Z. Chen, N. S. Gray and K. D. Westover, In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C, Proceedings of the National Academy of Sciences, 10.1073/pnas.1404639111, 111, 24, (8895-8900), (2014).
- Andrew G. Stephen, Dominic Esposito, Rachel K. Bagni and Frank McCormick, Dragging Ras Back in the Ring, Cancer Cell, 25, 3, (272), (2014).
- Jia Gao, Rongsheng Ma, Wei Wang, Na Wang, Ryan Sasaki, David Snyderman, Jihui Wu, Ke Ruan and Michael F. Olson, Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex, PLoS ONE, 9, 2, (e88098), (2014).
- Michael C. Burns, Qi Sun, R. Nathan Daniels, DeMarco Camper, J. Phillip Kennedy, Jason Phan, Edward T. Olejniczak, Taekyu Lee, Alex G. Waterson, Olivia W. Rossanese and Stephen W. Fesik, Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange, Proceedings of the National Academy of Sciences, 10.1073/pnas.1315798111, 111, 9, (3401-3406), (2014).
- Lingyan Jin, Weiru Wang and Guowei Fang, Targeting Protein-Protein Interaction by Small Molecules, Annual Review of Pharmacology and Toxicology, 54, 1, (435), (2014).
- Ina C. Rosnizeck, Daniel Filchtinski, Rui Pedro Lopes, Bärbel Kieninger, Christian Herrmann, Hans Robert Kalbitzer and Michael Spoerner, Elucidating the Mode of Action of a Typical Ras State 1(T) Inhibitor, Biochemistry, 53, 24, (3867), (2014).
- D R Cook, K L Rossman and C J Der, Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease, Oncogene, 33, 31, (4021), (2014).
- Michelle R. Arkin, Yinyan Tang and James A. Wells, Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality, Chemistry & Biology, 21, 9, (1102), (2014).
- Julian Blagg and Paul Workman, Chemical biology approaches to target validation in cancer, Current Opinion in Pharmacology, 17, (87), (2014).
- Jochen Spiegel, Philipp M. Cromm, Aymelt Itzen, Roger S. Goody, Tom N. Grossmann and Herbert Waldmann, Direct Targeting of Rab‐GTPase–Effector Interactions, Angewandte Chemie International Edition, 53, 9, (2498-2503), (2014).
- Martin Augsten, Anika Böttcher, Rainer Spanbroek, Ignacio Rubio and Karlheinz Friedrich, Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains, Cell Communication and Signaling, 10.1186/1478-811X-12-1, 12, 1, (1), (2014).
- Hilde van Hattum and Herbert Waldmann, Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time, Chemistry & Biology, 21, 9, (1185), (2014).
- Gunther Zimmermann, Carsten Schultz-Fademrecht, Philipp Küchler, Sandip Murarka, Shehab Ismail, Gemma Triola, Peter Nussbaumer, Alfred Wittinghofer and Herbert Waldmann, Structure Guided Design and Kinetic Analysis of Highly Potent Benzimidazole Inhibitors Targeting the PDEδ Prenyl Binding Site, Journal of Medicinal Chemistry, 57, 12, (5435), (2014).
- Lech-Gustav Milroy and Christian Ottmann, The Renaissance of Ras, ACS Chemical Biology, 9, 11, (2447), (2014).
- Lech-Gustav Milroy, Tom N. Grossmann, Sven Hennig, Luc Brunsveld and Christian Ottmann, Modulators of Protein–Protein Interactions, Chemical Reviews, 10.1021/cr400698c, 114, 9, (4695-4748), (2014).
- Gopinath Gudipudi, Someswar R. Sagurthi, Shyam Perugu, G. Achaiah and G. L. David Krupadanam, Rational design and synthesis of novel 2-(substituted-2H-chromen-3-yl)-5-aryl-1H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent, RSC Adv., 4, 99, (56489), (2014).
- Pravin Patil, Kareem Khoury, Eberhardt Herdtweck and Alexander Dömling, A Universal Isocyanide for Diverse Heterocycle Syntheses, Organic Letters, 16, 21, (5736), (2014).
- Chris R. Evelyn, Xin Duan, Jacek Biesiada, William L. Seibel, Jaroslaw Meller and Yi Zheng, Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1, Chemistry & Biology, 21, 12, (1618), (2014).
- Qi Sun, Jason Phan, Anders R. Friberg, DeMarco V. Camper, Edward T. Olejniczak and Stephen W. Fesik, A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand, Journal of Biomolecular NMR, 60, 1, (11), (2014).
- Julian Downward, RAS’s Cloak of Invincibility Slips at Last?, Cancer Cell, 25, 1, (5), (2014).
- Masami Kuriyama, Mina Shinozawa, Norihisa Hamaguchi, Seira Matsuo and Osamu Onomura, Palladium-Catalyzed Synthesis of Heterocycle-Containing Diarylmethanes through Suzuki–Miyaura Cross-Coupling, The Journal of Organic Chemistry, 10.1021/jo5009178, 79, 12, (5921-5928), (2014).
- Elisa Barile and Maurizio Pellecchia, NMR-Based Approaches for the Identification and Optimization of Inhibitors of Protein–Protein Interactions, Chemical Reviews, 10.1021/cr500043b, 114, 9, (4749-4763), (2014).
- David M. Dias and Alessio Ciulli, NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes, Progress in Biophysics and Molecular Biology, 10.1016/j.pbiomolbio.2014.08.012, 116, 2-3, (101-112), (2014).
- Duncan E. Scott, Matthias T. Ehebauer, Tara Pukala, May Marsh, Tom L. Blundell, Ashok R. Venkitaraman, Chris Abell and Marko Hyvönen, Using a Fragment-Based Approach To Target Protein-Protein Interactions, ChemBioChem, 14, 3, (332), (2013).
- Mary J. Harner, Andreas O. Frank and Stephen W. Fesik, Fragment-based drug discovery using NMR spectroscopy, Journal of Biomolecular NMR, 10.1007/s10858-013-9740-z, 56, 2, (65-75), (2013).
- Andy Barker, Jason G. Kettle, Thorsten Nowak and J. Elizabeth Pease, Expanding medicinal chemistry space, Drug Discovery Today, 18, 5-6, (298), (2013).
- Yuanxiang Wang, Christine E. Kaiser, Brendan Frett and Hong-yu Li, Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators, Journal of Medicinal Chemistry, 10.1021/jm3017706, 56, 13, (5219-5230), (2013).
- Till Maurer and Weiru Wang, NMR Study to Identify a Ligand-Binding Pocket in Ras, Inhibitors of the Ras Superfamily G-proteins, Part A, 10.1016/B978-0-12-416749-0.00002-6, (15-39), (2013).
- Christian W. Johnson and Carla Mattos, The Allosteric Switch and Conformational States in Ras GTPase Affected by Small Molecules, Inhibitors of the Ras Superfamily G-proteins, Part A, 10.1016/B978-0-12-416749-0.00003-8, (41-67), (2013).
- Priyanka Prakash and Alemayehu A. Gorfe, Lessons from computer simulations of Ras proteins in solution and in membrane, Biochimica et Biophysica Acta (BBA) - General Subjects, 10.1016/j.bbagen.2013.07.024, 1830, 11, (5211-5218), (2013).
- , Protein-Protein Interactions in Drug Discovery, (I), (2013).
- Xianghong Wu, Punit Upadhyaya, Miguel A. Villalona-Calero, Roger Briesewitz and Dehua Pei, Inhibition of Ras–effector interactions by cyclic peptides, Med. Chem. Commun., 4, 2, (378), (2013).
- Sarathy Kesavan and Lisa A Marcaurelle, Translational synthetic chemistry, Nature Chemical Biology, 9, 4, (210), (2013).
- Alessandro Di Domizio and Francesco Peri, Sugar-Based Inhibitors of Ras Activation, Inhibitors of the Ras Superfamily G-proteins, Part A, 10.1016/B978-0-12-416749-0.00005-1, (95-116), (2013).
- Andrei A. Ivanov, Fadlo R. Khuri and Haian Fu, Targeting protein–protein interactions as an anticancer strategy, Trends in Pharmacological Sciences, 10.1016/j.tips.2013.04.007, 34, 7, (393-400), (2013).
- Esther Castellano, Clare Sheridan, May Zaw Thin, Emma Nye, Bradley Spencer-Dene, Markus E. Diefenbacher, Christopher Moore, Madhu S. Kumar, Miguel M. Murillo, Eva Grönroos, Francois Lassailly, Gordon Stamp and Julian Downward, Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance, Cancer Cell, 24, 5, (617), (2013).
- H. J. Hocker, K.-J. Cho, C.-Y. K. Chen, N. Rambahal, S. R. Sagineedu, K. Shaari, J. Stanslas, J. F. Hancock and A. A. Gorfe, Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function, Proceedings of the National Academy of Sciences, 110, 25, (10201), (2013).
- Hans Robert Kalbitzer, Ina C. Rosnizeck, Claudia E. Munte, Sunilkumar Puthenpurackal Narayanan, Veronika Kropf and Michael Spoerner, Intrinsische allosterische Hemmung von Signalproteinen durch Stabilisierung gering besetzter, durch Hochdruck‐NMR‐Spektroskopie nachweisbarer Interaktionszustände, Angewandte Chemie, 125, 52, (14492-14496), (2013).
- Amy Donner, Interfacing with Ras, Science-Business eXchange, 6, 24, (2013).
- Clémentine Aguirre, Tim ten Brink, Olivier Walker, Florence Guillière, Dany Davesne, Isabelle Krimm and Eugene A. Permyakov, BcL-xL Conformational Changes upon Fragment Binding Revealed by NMR, PLoS ONE, 8, 5, (e64400), (2013).
- Michael J. Haas, Raising the Ras inhibitor bar, Science-Business eXchange, 6, 19, (2013).
- Miriam Schöpel, Katharina F. G. Jockers, Peter M. Düppe, Jasmin Autzen, Veena N. Potheraveedu, Semra Ince, King Tuo Yip, Rolf Heumann, Christian Herrmann, Jürgen Scherkenbeck and Raphael Stoll, Bisphenol A Binds to Ras Proteins and Competes with Guanine Nucleotide Exchange: Implications for GTPase-Selective Antagonists, Journal of Medicinal Chemistry, 56, 23, (9664), (2013).
- Monika Raj, Brooke N. Bullock and Paramjit S. Arora, Plucking the high hanging fruit: A systematic approach for targeting protein–protein interactions, Bioorganic & Medicinal Chemistry, 10.1016/j.bmc.2012.11.023, 21, 14, (4051-4057), (2013).
- Seth Nickerson, Stephen T. Joy, Paramjit S. Arora and Dafna Bar-Sagi, An Orthosteric Inhibitor of the RAS–SOS Interaction, Inhibitors of the Ras superfamily G-proteins, Part B, 10.1016/B978-0-12-420146-0.00002-0, (25-39), (2013).
- Martin J. Drysdale, Fragment-based Drug Discovery: the Shape of Things to Come, Australian Journal of Chemistry, 10.1071/CH13255, 66, 12, (1544), (2013).
- Clare Sheridan and Julian Downward, Inhibiting the RAS–PI3K Pathway in Cancer Therapy, Inhibitors of the Ras superfamily G-proteins, Part B, 10.1016/B978-0-12-420146-0.00005-6, (107-136), (2013).
- Hans Robert Kalbitzer and Michael Spoerner, State 1(T) Inhibitors of Activated Ras, Inhibitors of the Ras Superfamily G-proteins, Part A, 10.1016/B978-0-12-416749-0.00004-X, (69-94), (2013).
- Brendan Frett, Yuanxiang Wang and Hong-yu Li, Targeting the K-Ras/PDEδProtein-Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage?, ChemMedChem, (n/a), (2013).
- Gideon Bollag and Chao Zhang, Pocket of opportunity, Nature, 503, 7477, (475), (2013).
- Fumi Shima, Yoko Yoshikawa, Shigeyuki Matsumoto and Tohru Kataoka, Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras·GTP–Effector Interaction, Inhibitors of the Ras superfamily G-proteins, Part B, 10.1016/B978-0-12-420146-0.00001-9, (1-23), (2013).
- F. Shima, Y. Yoshikawa, M. Ye, M. Araki, S. Matsumoto, J. Liao, L. Hu, T. Sugimoto, Y. Ijiri, A. Takeda, Y. Nishiyama, C. Sato, S. Muraoka, A. Tamura, T. Osoda, K.-i. Tsuda, T. Miyakawa, H. Fukunishi, J. Shimada, T. Kumasaka, M. Yamamoto and T. Kataoka, In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction, Proceedings of the National Academy of Sciences, 110, 20, (8182), (2013).
- Andreas O. Frank, Michael D. Feldkamp, J. Phillip Kennedy, Alex G. Waterson, Nicholas F. Pelz, James D. Patrone, Bhavatarini Vangamudi, DeMarco V. Camper, Olivia W. Rossanese, Walter J. Chazin and Stephen W. Fesik, Discovery of a Potent Inhibitor of Replication Protein A Protein–Protein Interactions Using a Fragment-Linking Approach, Journal of Medicinal Chemistry, 56, 22, (9242), (2013).
- Carolyn Bentley, Stefanie S. Jurinka, Noelyn M. Kljavin, Steffan Vartanian, Sree R. Ramani, Lino C. Gonzalez, Kebing Yu, Zora Modrusan, Pan Du, Richard Bourgon, Richard M. Neve and David Stokoe, A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation, Biochemical Journal, 10.1042/BJ20121578, 452, 2, (313-320), (2013).
- Robert Lütjens, Benjamin Perry, Dominik Schelshorn and Jean-Philippe Rocher, New technologies enabling the industrialization of allosteric modulator discovery, Drug Discovery Today: Technologies, 10, 2, (e253), (2013).
- Raymond R. Mattingly, Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins, ISRN Oncology, 2013, (1), (2013).
- Vladimir Khazak, Susanne Eyrisch, Juran Kato, Fuyuhiko Tamanoi and Erica A. Golemis, A Two-Hybrid Approach to Identify Inhibitors of the RAS–RAF Interaction, Inhibitors of the Ras Superfamily G-proteins, Part A, 10.1016/B978-0-12-416749-0.00010-5, (213-248), (2013).
- Hans Robert Kalbitzer, Ina C. Rosnizeck, Claudia E. Munte, Sunilkumar Puthenpurackal Narayanan, Veronika Kropf and Michael Spoerner, Intrinsic Allosteric Inhibition of Signaling Proteins by Targeting Rare Interaction States Detected by High‐Pressure NMR Spectroscopy, Angewandte Chemie International Edition, 52, 52, (14242-14246), (2013).
- Gunther Zimmermann, Björn Papke, Shehab Ismail, Nachiket Vartak, Anchal Chandra, Maike Hoffmann, Stephan A. Hahn, Gemma Triola, Alfred Wittinghofer, Philippe I. H. Bastiaens and Herbert Waldmann, Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling, Nature, 497, 7451, (638), (2013).
- Ina C. Rosnizeck, Michael Spoerner, Tobias Harsch, Sandra Kreitner, Daniel Filchtinski, Christian Herrmann, Daniel Engel, Burkhard König and Hans Robert Kalbitzer, Metall-Bis(2-picolyl)amin-Komplexe als Zustand-1(T)-Inhibitoren für aktiviertes Ras-Protein, Angewandte Chemie, 124, 42, (10799), (2012).
- Dennis L. Buckley, Jeffrey L. Gustafson, Inge Van Molle, Anke G. Roth, Hyun Seop Tae, Peter C. Gareiss, William L. Jorgensen, Alessio Ciulli and Craig M. Crews, Niedermolekulare Inhibitoren der Wechselwirkung zwischen der E3‐Ligase VHL und HIF1α, Angewandte Chemie, 124, 46, (11630-11634), (2012).
- Dennis L. Buckley, Jeffrey L. Gustafson, Inge Van Molle, Anke G. Roth, Hyun Seop Tae, Peter C. Gareiss, William L. Jorgensen, Alessio Ciulli and Craig M. Crews, Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α, Angewandte Chemie International Edition, 51, 46, (11463-11467), (2012).
- Inge Van Molle, Andreas Thomann, Dennis L. Buckley, Ernest C. So, Steffen Lang, Craig M. Crews and Alessio Ciulli, Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface, Chemistry & Biology, 10.1016/j.chembiol.2012.08.015, 19, 10, (1300-1312), (2012).
- Ina C. Rosnizeck, Michael Spoerner, Tobias Harsch, Sandra Kreitner, Daniel Filchtinski, Christian Herrmann, Daniel Engel, Burkhard König and Hans Robert Kalbitzer, Metal-Bis(2-picolyl)amine Complexes as State 1(T) Inhibitors of Activated Ras Protein, Angewandte Chemie International Edition, 51, 42, (10647), (2012).
- Elena Sacco, Michela Spinelli and Marco Vanoni, Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present), Expert Opinion on Therapeutic Patents, 10.1517/13543776.2012.728586, 22, 11, (1263-1287), (2012).
- Mark Jeeves, Lee Quill and Michael Overduin, Structure‐based Drug Design Using NMR, eMagRes, (231-240), (2015).
- Lee Quill, Michael Overduin and Mark Jeeves, Structure‐Aided Drug Discovery and NMR‐Based Screening, Reviews in Cell Biology and Molecular Medicine, (1-28), (2016).
- Adrienne D. Cox, Stephen W. Fesik, Alec C. Kimmelman, Ji Luo and Channing J. Der, Drugging the undruggable RAS: Mission Possible?, Nature Reviews Drug Discovery, 10.1038/nrd4389, 13, 11, (828-851), (2014)., (2014).
- Jochen Spiegel, Philipp M Cromm, Gunther Zimmermann, Tom N Grossmann and Herbert Waldmann, Small-molecule modulation of Ras signaling, Nature Chemical Biology, 10.1038/nchembio.1560, 10, 8, (613-622), (2014)., (2014).
- Michael McCarthy, Priyanka Prakash and Alemayehu A. Gorfe, Computational allosteric ligand binding site identification on Ras proteins, Acta Biochimica et Biophysica Sinica, 10.1093/abbs/gmv100, (gmv100), (2015).
